- Home
- CFFI vs CTNM Comparison
CFFI vs CTNM Comparison
Compare CFFI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFFI
- CTNM
- Stock Information
- Founded
- CFFI 1927
- CTNM 2009
- Country
- CFFI United States
- CTNM United States
- Employees
- CFFI N/A
- CTNM N/A
- Industry
- CFFI Major Banks
- CTNM
- Sector
- CFFI Finance
- CTNM
- Exchange
- CFFI Nasdaq
- CTNM Nasdaq
- Market Cap
- CFFI 218.0M
- CTNM 248.7M
- IPO Year
- CFFI 1998
- CTNM 2024
- Fundamental
- Price
- CFFI $67.65
- CTNM $11.35
- Analyst Decision
- CFFI
- CTNM Strong Buy
- Analyst Count
- CFFI 0
- CTNM 5
- Target Price
- CFFI N/A
- CTNM $22.20
- AVG Volume (30 Days)
- CFFI 5.7K
- CTNM 225.6K
- Earning Date
- CFFI 10-28-2025
- CTNM 11-05-2025
- Dividend Yield
- CFFI 2.72%
- CTNM N/A
- EPS Growth
- CFFI 32.15
- CTNM N/A
- EPS
- CFFI 7.56
- CTNM N/A
- Revenue
- CFFI $122,075,000.00
- CTNM N/A
- Revenue This Year
- CFFI N/A
- CTNM N/A
- Revenue Next Year
- CFFI N/A
- CTNM N/A
- P/E Ratio
- CFFI $8.95
- CTNM N/A
- Revenue Growth
- CFFI 7.42
- CTNM N/A
- 52 Week Low
- CFFI $53.14
- CTNM $3.35
- 52 Week High
- CFFI $89.90
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- CFFI 45.23
- CTNM 53.80
- Support Level
- CFFI $65.50
- CTNM $10.65
- Resistance Level
- CFFI $69.58
- CTNM $12.12
- Average True Range (ATR)
- CFFI 1.56
- CTNM 1.01
- MACD
- CFFI -0.45
- CTNM -0.25
- Stochastic Oscillator
- CFFI 34.19
- CTNM 33.75
About CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.